Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study

BACKGROUND: A gap remains in documenting the impact of anti-tumor necrosis factor therapy on disease burden in ulcerative colitis (UC) patients treated in a real-world setting. The use of patient-reported outcomes (PROs) has been discussed as a primary endpoint in the context of the FDA PRO Guidance...

Descripción completa

Detalles Bibliográficos
Autores principales: Bessissow, Talat, Nguyen, Geoffrey C, Tarabain, Osman, Peyrin-Biroulet, Laurent, Foucault, Nathalie, McHugh, Kevin, Ruel, Joannie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Observational Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494926/
https://www.ncbi.nlm.nih.gov/pubmed/36160646
http://dx.doi.org/10.3748/wjg.v28.i34.5058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494926/
https://www.ncbi.nlm.nih.gov/pubmed/36160646
http://dx.doi.org/10.3748/wjg.v28.i34.5058

Ejemplares similares